CpG oligodeoxynucleotides: postexposure prophylaxis for prion diseases?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1348, 2002-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IFN- : a molecular target for bone diseases?

Inpharma, Vol. 1, Iss. 1337, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Anti-CD137 immunotherapy for autoimmune diseases?

Inpharma, Vol. 1, Iss. 1373, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

A Review of the Role of CpG Oligodeoxynucleotides as Toll-Like Receptor 9 Agonists in Prophylactic and Therapeutic Vaccine Development in Infectious Diseases

By Gupta Kaveri

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 137-145

Adis International

Access to resources Recommend Favorite

Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species

By Manuja Anju Manuja Balvinder K. Kaushik Jyoti Singha Harisankar Singh Raj Kumar

Immunopharmacology and Immunotoxicology, Vol. 35, Iss. 5, 2013-10 ,pp. : 535-544

Informa Healthcare

Access to resources Recommend Favorite

CpG Oligodeoxynucleotides: A Novel Therapeutic Approach For Atopic Disorders

Current Drug Targets. Inflammation & Allergy, Vol. 2, Iss. 3, 2003-09 ,pp. : 199-205

Bentham Science Publishers

Access to resources Recommend Favorite